Other areas of active research address CAR T in combination with other lymphoma-directed therapies, and mechanisms of CAR T resistance. This review focuses on the FDA-approved anti-CD19 CAR T products for B-cell lymphomas, management of CAR T-cell-associated toxicities, approaches to bridging ...
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit th
Adoptive T cell therapy, including chimeric antigen receptor (CAR) T cells, has achieved significant success in targeted cancer cell eradication [1,2]. Although the FDA has approved CAR-T cell therapies for certain hematological malignancies, a significant proportion of patients relapse within one ye...
proving its therapeutic anti-cancer potential [36]. Indeed, two CAR-T cell therapies Tisagenlecleucel and Axicabtagen-ciloleucel, were approved by the European Medical Agency (EMA) and the Food and Drug Administration (FDA) for the treatment of patients with relapsed...
CAR T-cell therapy are shifting the treatment landscape and what he’s anticipating will be presented at upcoming conferences. “One of the things I know I've learned about mantle cell lymphoma is that if you wait six months, something new will come down the come down the pipeline,” Dr ...
Nevertheless, various barriers restrict the efficacy and/or prevent the widespread use of CAR T cell therapies in these patients as well as in those with other cancers, particularly solid tumours. Key challenges relating to CAR T cells include severe toxicities, restricted trafficking to, ...
CAR T-Cell therapies in lymphoma: current landscape, ongoing investigations, and future directions Chimeric antigen receptor (CAR) T-cell therapy has significantly improved outcomes for patients with relapsed/refractory large B-cell lymphoma, mantle cell... JE Haydu,JS Abramson - 《Journal of Cancer...
Recent advances and current challenges in CAR-T cell therapy Rapid advancements in the field of immunotherapy have significantly improved cancer treatments. Specifically, an individualized cell-based modality which i... R Joy,K Phair,RBD O'Hara - 《Biotechnology Letters》 被引量: 0发表: 2024年 ...
What about CAR T-cells in T-ALL? T-ALL is more aggressive and chemoresistant than B-ALL with a lack of innovative therapies and efficient immunotherapy option. Relapsed/refractory T-ALL have particularly dismal outcome. Three main barriers render uneasy to develop CAR T-cells against T-ALL: ...
(CAR) T or NK cells, to exert anti-tumor effects. Over the past decades, CAR-T cell therapies have gained significant traction in oncological treatment, offering hope through their targeted approach. However, the potential adverse effects associated with CAR-T cells, including cytokine release ...